Galera Therapeutics, Inc.

Galera Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies that cater primarily to radiation oncology. The company's leading asset, a selective small molecule inhibitor of superoxide dismutase, is designed to mitigate the adverse effects of radiation by reducing severe oral mucositis in patients undergoing cancer treatment. Targeting an unmet need in the oncology sector, Galera's research and development efforts seek to improve the quality of life for patients by addressing serious complications associated with cancer therapies. Operating at the intersection of healthcare and biotechnology, Galera Therapeutics partners with medical institutions and research organizations to advance their therapeutic candidates. In the competitive landscape of biopharmaceuticals, Galera's focus on oncology supportive care highlights its niche in contributing to a growing field of precision medicine and patient-focused innovations.